Written by: Kirollos Hanna, PharmD, BCPS, BCOP, Mayo Clinic College of Medicine and M Health Fairview and Kayla Randle, PharmD, BCOP, Kaiser Permanente – Southwood Oncology Clinic
Download Here

Brentuximab vedotin (Adcetris) is an CD30-directed antibody drug conjugate (ADC) indicated as front-line treatment for patients with classical stage III/IV Hodgkin’s Lymphoma (cHL) or CD30-expressing peripheral T-cell lymphomas (PTCL) in combination with multiagent chemotherapy.1 This PQI will review how to safely manage select toxicities associated with brentuximab vedotin.
Continue reading Brentuximab Vedotin (Adcetris®): Neuropathy and Neutropenia Management

Read More